Evidence map›Paper›PMID 25546418›Full record

ArticlePloS one2014

Characterization of the murine myeloid precursor cell line MuMac-E8.

Stephan Fricke, Cathleen Pfefferkorn, Doris Wolf, Sina Riemschneider, Janine Kohlschmidt, Nadja Hilger, Christiane Fueldner, Jens Knauer, Ulrich Sack, Frank Emmrich and 1 more

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Stephan FrickeFraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany; Institute of Clinical Immunology, University of Leipzig, Leipzig, Germany; Translational Centre for Regenerative Medicine, University of Leipzig, Leipzig, Germany.
Cathleen PfefferkornFraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
Doris WolfFraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany; Department of Surgery, Research Laboratories, University of Leipzig, Leipzig, Germany.
Sina RiemschneiderFraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
Janine KohlschmidtFraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
Nadja HilgerFraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
Christiane FueldnerFraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
Jens KnauerFraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
Ulrich SackFraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany; Institute of Clinical Immunology, University of Leipzig, Leipzig, Germany; Translational Centre for Regenerative Medicine, University of Leipzig, Leipzig, Germany.
Frank EmmrichFraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany; Institute of Clinical Immunology, University of Leipzig, Leipzig, Germany; Translational Centre for Regenerative Medicine, University of Leipzig, Leipzig, Germany.
Jörg LehmannFraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Starting point for the present work was the assumption that the cell line MuMac-E8 represents a murine cell population with stem cell properties. Preliminary studies already pointed to the expression of stem-cell associated markers and a self-regenerative potential of the cells. The cell line MuMac-E8 should be examined for their differential stage within stem cell hierarchy. MuMac-E8 cells were derived from a chimeric mouse model of arthritis. It could be shown that MuMac-E8 cells express mRNA of some genes associated with pluripotent stem cells (Nanog, Nucleostemin), of genes for hematopoietic markers (EPCR, Sca-1, CD11b, CD45), for the mesenchymal marker CD105 and of genes for the neural markers Pax-6 and Ezrin. In methylcellulose and May-Grünwald-Giemsa staining, hematopoietic colonies were obtained but the hematopoietic system of lethally irradiated mice could not be rescued. Osteogenic differentiation was not detectable. Thus, it became evident that MuMac-E8 represents not a stem cell line. However, MuMac-E8 cells expressed several myeloid surface markers (i.e. CD11b, F4/80, CD14, CD64), showed phagocytosis and is capable of producing nitric oxide. Thus, this cell line seems to be arrested an advanced stage of myeloid differentiation. Adherence data measured by impedance-based real-time cell analysis together with cell morphology data suggested that MuMac-E8 represents a new macrophage precursor cell line exhibiting weak adherence. This cell line is suitable as an in-vitro model for testing of macrophage functions. Moreover, it might be also useful for differentiation or reprogramming studies.

Indexed as

Cell DifferentiationCell LineCell LineageAnimalsHematopoiesisHumansMacrophagesMiceMice, TransgenicOsteogenesisStem Cells

Identifiers

PMID25546418
PMCPMC4278753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.